Showing results (241-250 of 270) with videos related to
Sort By:
Pageof 27
The New England Journal of Medicine|June 2, 2025
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast CancerMario Campone, Michelino De Laurentiis, Komal Jhaveri, et al.European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 studyValentina Guarneri, Franco Bassan, Vittorina Zagonel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.Cancer Treatment Reviews|January 31, 2020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysisFrancesco Schettini, Tomás Pascual, Benedetta Conte, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.Ebiomedicine|January 6, 2022
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerAleix Prat, Valentina Guarneri, Tomás Pascual, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2026
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancerMaria Vittoria Dieci, Elisa Gasparini, Lorenzo Nicolè, et al.BMC Medicine|November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.Cell|April 2, 2026
A 3D morphogenetic blueprint for metastatic outgrowth in breast cancerRobin Caire, Roberta Bordo, Francesca Zanconato, et al.Pageof 27